Search clinical trials for: liposomal irinotecan

Total 3381 results

XIANG YANQUN

Not yet recruiting

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Nasopharyngeal Cancer

China
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
Hebei Medical University Fourth Hospital

Not yet recruiting

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Rectal Cancer
Harbin Medical University

Not yet recruiting

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Colorectal Cancer
Hebei Medical University Fourth Hospital

Not yet recruiting

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Colorectal Cancer
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
Fudan University

Recruiting

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
University of Wisconsin, Madison
Ipsen

Recruiting

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Sun Yat-sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Rhabdomyosarcoma, Child
Reema A. Patel

Recruiting

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Colorectal Cancer | Pancreatic Cancer

United States
National Cancer Center, Korea
Seoul National University Bundang Hospital

Recruiting

Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan

Pancreatic Cancer

Korea, Republic of
Shanghai Children's Medical Center
Shanghai Children's Hospital

Recruiting

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

Hepatoblastoma

China
Seoul National University Hospital

Recruiting

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer (NaliCap)

Pancreatic Cancer

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Peritoneal Carcinomatosis | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Malignant Uterine Neoplasm | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Colorectal Carcinoma | Stage... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor | Recurrent Kidney Wilms Tumor | Anaplastic Kidney Wilms Tumor

United States, Canada, Puerto Rico, Australia, New Zealand, Saudi Arabia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Metastatic Sarcoma | Resectable Sarcoma | Recurrent Sarcoma

United States
University of Wisconsin, Madison
Ipsen

Recruiting

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Odense University Hospital; Medical University of Vienna; Maastricht University... and other collaborators

Recruiting

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (NAPAN)

Metastatic Pancreatic Cancer

Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...
Servier

Recruiting

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer (LyRICX)

Esophageal Cancer

Netherlands
Centro Ricerche Cliniche di Verona

Recruiting

A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer (nITRo)

Pancreatic Adenocarcinoma

Italy
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

PRETEXT I Hepatoblastoma | PRETEXT II Hepatoblastoma | PRETEXT III Hepatoblastoma | PRETEXT IV Hepatoblastoma

United States, Canada, Puerto Rico, Australia, Japan, Brazil
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States
Ipsen

Active, not recruiting

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

Metastatic Adenocarcinoma of the Pancreas

United States, Spain, Hungary, France, Portugal, Korea, Republic of, Germany, United Kingdom, Austria, Italy, Israel, Australia, Brazil, Czechia, Belgium, Russian Federation, Canada, Greece
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Hepatoblastoma | Fibrolamellar Carcinoma | Childhood Hepatocellular Carcinoma | Childhood Malignant Liver Neoplasm | Hepatocellular Malignant Neoplasm, Not Otherwise Specified

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Servier Affaires Médicales

Active, not recruiting

RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)

Pancreatic Cancer Metastatic

Germany
St. Jude Children's Research Hospital

Active, not recruiting

Mature B-Cell Lymphoma And Leukemia Study III

Mature B-Cell Lymphoma

United States, Singapore, Egypt
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Malignant Solid Neoplasm

United States
Nelson Yee
Ipsen

Active, not recruiting

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Locally Advanced Pancreatic Carcinoma(LAPC)

United States
Federation Francophone de Cancerologie Digestive

Active, not recruiting

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI (FUNGEMAX)

Metastatic Pancreatic Cancer

France, Martinique
Asan Medical Center
Hallym University Medical Center

Active, not recruiting

Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma (NASOX)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
University of Florida
Ipsen

Active, not recruiting

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC; Ipsen

Withdrawn

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Triple Negative Breast Cancer | Brain Metastases

United States
University of California, San Francisco
National Cancer Institute (NCI); Ipsen

Completed

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

High Grade Glioma

United States
The Christie NHS Foundation Trust
University of Leeds; National Institute for Health Research, United Kingdom; ...

Active, not recruiting

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NET02)

Oncology | Neuroendocrine Carcinoma

United Kingdom
Devalingam Mahalingam
Amgen

Withdrawn

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | KRAS P.G12C

United States
ERYtech Pharma

Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)

Pancreatic Adenocarcinoma

United States, United Kingdom, France
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
Washington University School of Medicine
Ipsen

Completed

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Pancreatic Cancer | Pancreas Cancer | Cancer of the Pancreas

United States
Ludwig-Maximilians - University of Munich

Active, not recruiting

First-line Therapy in Metastatic PDAC (FOOTPATH)

Metastatic Pancreatic Cancer

Germany

Search clinical trials for: liposomal irinotecan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations